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Abstract





ated  the  efficacy  of  LDL  reduction,  the  rate  of  adverse 
events, and the progression of atherosclerosis.
Methods  Between  July  1992  and  April  2009,  we  per-







and  after  each  therapy.  Blood  count,  electrolytes,  total 





















HELP  apheresis  were  rare. This  data  is  in  line  with  the 
















































with  homozygous  or  severe  heterozygous  FH  cannot  be 
treated sufficiently by drug therapy and diet and they require 
additional extracorporeal treatment [5]. LDL-C apheresis is 
a  last  treatment  option  for  hypercholesterolemic  patients 
resistant to conservative lipid-lowering therapy [6–9].




proteins  (Baxter,  Munich,  Germany);  and  DSA = Dextran 
Sulphate  Adsorption  (Kaneka,  Osaka,  Japan)).  Another 
method focuses on Membrane Differential Filtration (MDF; 
Diamed, Cologne, Germany). The method of Heparin-in-


































































sence  of  heparin.  The  patient’s  blood  is  separated  from 
the corpuscular blood elements. The plasma is then mixed 
with a sodium acetate buffer (pH 4.85) and heparin. These 












































































nation  of  LDL-C  (measurement  immediately  before  and 
Patient No. Start of HELP End of HELP Number of procedures
  1 16.12.1998 12.01.2004 226
  2 25.04.2001 18.02.2004 68
  3 16.10.1992 20.09.1996 185
  4 02.02.1996 08.04.2009 631
  5 14.03.2007 07.04.2009 101
  6 09.11.1994 26.05.1998 50
  7 25.04.2007 15.04.2009 93
  8 11.11.2005 03.04.2009 111
  9 11.12.2003 26.10.2007 67
10 03.08.1999 09.04.2009 419
11 30.06.1992 15.04.2009 758
12 08.07.1992 14.04.2009 751
13 10.03.1994 04.05.2005 527
14 26.04.2007 15.04.2009 91
15 11.02.2003 15.04.2009 291
16 17.01.2007 14.04.2009 116
17 21.04.1994 15.04.2009 686
18 05.05.1994 16.01.2004 472
19 11.01.1993 14.04.2009 790
20 03.03.2005 14.04.2009 56
21 23.05.2005 06.04.2009 169
22 17.05.1999 29.03.2004 230
23 15.04.1996 08.04.2009 437
24 16.09.2003 08.04.2009 249
25 16.04.1998 17.01.2001 65
26 05.05.1998 09.04.2009 463







All  patients  were  on  CSE  inhibitor  before  the  initial 
HELP therapy (simvastatin 51.9%; atorvastatin 37%, pra-
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